
Opinion|Videos|April 28, 2025
Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches
Experts discuss the preliminary results of the PEAK study on the combination of bezuclastinib and sunitinib in second-line gastrointestinal stromal tumors (GIST), its potential to address heterogeneous resistance mutations, and how mutation-specific, biomarker-driven approaches in ongoing trials like INSIGHT may shift the treatment paradigm compared with traditional line-of-therapy strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- The
PEAK study is evaluating the combination of bezuclastinib plus sunitinib vs sunitinib alone in second-line GIST. Can you walk us though the preliminary results and comment on how might this combination approach address the challenge of heterogeneous resistance mutations we see after imatinib failure? - How is this combination approach different from our current sequential TKI approach, and how might this combined targeting strategy address the challenge of heterogeneous resistance mutations we see after imatinib failure?
- What would you consider a clinically meaningful improvement over sunitinib monotherapy that would change your practice?
- Ongoing trials such as
INSIGHT are taking a more targeted biomarker-driven approach by focusing on specific molecular subgroups. How might these mutation-specific approaches change our treatment paradigm compared with the traditional line-of-therapy approach?
Please feel free to highlight any other ongoing trials of note.
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


